Primecap Management
ALLO icon

Primecap Management’s Allogene Therapeutics ALLO Stock Holding History

Primecap Management’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.3M Buy
13,123,440
+4,743,600
+57% +$10.4M 0.02% 231
2026
Q1 		$20.4M Buy
8,379,840
+240,000
+3% +$481K 0.02% 231
2025
Q4 		$11.2M Buy
8,139,840
+1,060,532
+15% +$1.4M 0.01% 250
2025
Q3 		$8.78M Buy
7,079,308
+1,360,168
+24% +$1.62M 0.01% 263
2025
Q2 		$6.46M Buy
5,719,140
+787,300
+16% +$1.05M 0.01% 277
2025
Q1 		$7.2M Buy
4,931,840
+4,500
+0.1% +$8.48K 0.01% 267
2024
Q4 		$10.5M Sell
4,927,340
-740,920
-13% -$1.83M 0.01% 254
2024
Q3 		$15.9M Sell
5,668,260
-1,966
-0% -$5.24K 0.01% 247
2024
Q2 		$13.2M Buy
5,670,226
+221,840
+4% +$654K 0.01% 249
2024
Q1 		$24.4M Buy
5,448,386
+166,500
+3% +$695K 0.02% 222
2023
Q4 		$17M Sell
5,281,886
-2,500
-0% -$7.09K 0.01% 237
2023
Q3 		$16.8M Sell
5,284,386
-352,300
-6% -$1.54M 0.01% 238
2023
Q2 		$28M Sell
5,636,686
-132,300
-2% -$716K 0.02% 216
2023
Q1 		$28.5M Buy
5,768,986
+825,070
+17% +$5.29M 0.02% 208
2022
Q4 		$31.1M Buy
4,943,916
+51,050
+1% +$473K 0.03% 192
2022
Q3 		$52.8M Buy
4,892,866
+9,900
+0.2% +$135K 0.05% 169
2022
Q2 		$55.7M Sell
4,882,966
-23,300
-0.5% -$207K 0.05% 171
2022
Q1 		$44.7M Buy
4,906,266
+244,451
+5% +$2.55M 0.03% 198
2021
Q4 		$69.6M Buy
4,661,815
+1,057,515
+29% +$18.7M 0.05% 175
2021
Q3 		$92.6M Buy
3,604,300
+27,270
+0.8% +$647K 0.07% 158
2021
Q2 		$93.3M Buy
3,577,030
+2,271,630
+174% +$64.8M 0.06% 157
2021
Q1 		$46.1M Buy
1,305,400
+67,000
+5% +$2.26M 0.03% 198
2020
Q4 		$31.3M Buy
+1,238,400
New +$40.4M 0.02% 210

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Primecap Management's ALLO Position: Q2 2026 in Review

Primecap Management increased its Allogene Therapeutics (ALLO) stake by 57% in Q2 2026, buying an estimated $10.4M and bringing the position to 13,123,440 shares worth $27.3M. The position accounts for 0.02% of the portfolio, ranked #231.

Primecap Management first reported a position in ALLO in Q4 2020 and has held it in 23 quarters since. The position peaked at $93.3M in Q2 2021. 208 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Primecap Management held 13,123,440 shares of Allogene Therapeutics worth $27.3M as of Q2 2026.
  • Primecap Management bought 4,743,600 Allogene Therapeutics shares in Q2 2026, an estimated $10.4M.
  • Allogene Therapeutics made up 0.02% of Primecap Management's portfolio in Q2 2026, its #231 holding.
  • Primecap Management first reported a position in Allogene Therapeutics in Q4 2020 and has held it in 23 quarters since.
  • Primecap Management's Allogene Therapeutics position peaked at $93.3M in Q2 2021.
  • 208 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Primecap Management's 13F filing for Q2 2026, filed 14 Aug 2026.